Bladder cancer
NEW --- Handling AEs of targeted therapies for metastatic UCa

Katia (72 years old)

Katia, 72 years old, loves knitting. Her passion is so unbridled that the scarf she is making for her niece is now 2 metres long.

She was diagnosed with UCa of bladder with lung metastases, for which she received 6 cycles of gemcitabine + cisplatin. At the end of chemotherapy, CT revealed new lung lesions; pembrolizumab was started. 9 months later, she shows again progressive disease.

Assessment summary:

  • No relevant medical history
  • ECOG PS: 2; increasing breathlessness and cough
  • CT chest, abdomen and pelvis: enlarged lesions in lungs
  • FGFR2/3 status in tumour tissue specimen: activating FGFR3 gene fusion

The patient started erdafitinib with partial response, but 2 months later, she develops blurred vision making her unable to drive. On ophthalmologic examination, a diagnosis of grade 2 central serous chorioretinopathy was made. She is being followed up by an ophthalmologist with regular examinations. 

Erdafitinib treatment was withheld from the onset of the eye disorder, and 3 weeks later, the ocular symptoms resolved completely. After discussing with the ophthalmologist in detail you are deciding the next step. 

Which of the following options would you choose for this patient?